Avon Lifesciences Ltd 1 22nd ANNUAL REPORT Board of Directors Mr. Ajit Kamath Mr. Manoj Jain Mr. Rajendra Kaimal Independent Directors Dr. Sunil Pitroda Ms. Zeenat Pathan Ms. Komal Jajodia Company Secretary Mr. Jignesh Patel Registered Office Survey No. 18, Yawapur Village, Sadasivpet Mandal, Medak Dist., Telangana - 502 291. Corporate Office H Wing, 4th Floor, Tex Centre, Off Saki Vihar Road, Chandivali, Andheri (East), Mumbai -400072 Phone: 022-28037777 Fax: 022-285575852 Statutory Auditors M/s. Mukesh Mehta & Associates, Chartered Accountants, 320, Hammersmith Ind. Premises, Narayan Pathare Marg, Off Sitladevi Temple Road, Mahim (W), Mumbai - 400 016 Manufacturing Facilities 1. Plot No. E-2, Chincholi Industrial Area Solapur, Maharastra 2. Survey No. 18, Yawapur Village, Sadasivpet Mandal, Medak Dist., Telangana - 502 291. (Non-operational) Bankers State Bank of India Axis Bank Limited Punjab National Bank Indian Overseas Bank Karur Vysya Bank Registrars & Share Transfer Agents XL Softech Limited, 3, Sagar Society, Road No. 2, Banjara Hills, Hyderabad-500 034. Phone no.:040-23545913 /14 / 15. Corporate Information AVON LIFESCIENCES LIMITED (Formerly Avon Organics Ltd) CIN: L24110TG1993PLC016112 1. Corporate Information ............................................... 1 2. Notice ........................................................... 2 3. Director's Report ................................................... 8 4. Annexure to Director's Report ........................................ 12 5. Details of Directors Seeking Appointment/Reappointment .................. 14 6. Secretarial Audit Report ............................................. 15 7. Extract of Annual Return ............................................ 18 8. Management Discussion & Analysis Report ............................. 25 9. Report on Corporate Governance ..................................... 27 10. Auditor's Report ................................................... 37 11. Annexure to Auditor's Report ......................................... 39 12. Balance Sheet .................................................... 41 13. Statement of Profit and Loss Account .................................. 42 14. Notes to Financial Statement ......................................... 43 15. Notes to Accounts ................................................. 49 16. Cash Flow Statement............................................... 53 17. Proxy Form ...................................................... 55 18. Attendance Slip ................................................... 56 19. Assent/Dissent Form for voting on AGM Resolutions ...................... 57 Contents Particulars Page No.
31
Embed
Corporate Information2. To appoint a Director in place of Mr. Ajit Kamath (DIN: 00032799), who retires by rotation and is eligible for re-appointment. 3. To appoint a Director in place
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Avon Lifesciences Ltd
1
22nd ANNUAL REPORT
Board of Directors Mr. Ajit KamathMr. Manoj JainMr. Rajendra Kaimal
NOTICENOTICE IS HEREBY GIVEN THAT the 22nd Annual General Meeting of Avon Lifesciences Limited (formerly known as Avon Organics Ltd) will be held on Wednesday, 30th day of September, 2015 at 10 a.m. at Hotel Daspalla, Road No. 37, Jubilee Hills, Hyderabad - 500033, Telangana, to transact the following business:
ORDINARY BUSINESS:
1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2015, together with the Reports of the Board of Directors and the Auditors thereon.
2. To appoint a Director in place of Mr. Ajit Kamath (DIN: 00032799), who retires by rotation and is eligible for re-appointment.
3. To appoint a Director in place of Mr. Rajendra Kaimal (DIN: 00032839), who retires by rotation and is eligible for re-appointment.
4. Appointment of Statutory Auditors
To consider and if thought fit, to pass with or without modification(s) the following resolution as an Ordinary Resolution:
"RESOLVED THAT pursuant to the provisions of Section 139 and all other applicable provisions, if any, of the Companies Act, 2013 and the Rules framed thereunder, as amended from time to time, the Company hereby ratifies the appointment of M/s. Mukesh Mehta & Associates, Chartered Accountants (Registration No. 116309W), as Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting (AGM) till the conclusion of the twenty-third AGM of the Company to be held in the year 2016 at such remuneration plus service tax, out-of-pocket, travelling and living expenses, etc., as may be mutually agreed between the Board of Directors of the Company and the Auditors.
SPECIAL BUSINESS:
5. Appointment of Ms. Zeenat Pathan (DIN: 07153363) as an Independent Director & Designated as Woman Director.
To consider and if thought fit, to pass with or without modification, the following resolution as an Ordinary Resolution:
"RESOLVED that pursuant to the provisions of Sections 149, 150, 152 and any other applicable provisions of the Companies Act, 2013 (the "Act") and the Companies Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) read with Schedule IV to the Act and Clause 49 of the Listing Agreement, Ms. Zeenat Pathan (DIN: 07153363), who was appointed as an Additional Director of the Company by the Board of Directors with effect from 09th April, 2015, in terms of Section 161(1) of the Act and whose term of office expires at the Annual General Meeting and in respect of whom the Company has received a notice in writing from a member proposing his candidature for the office of Director, be and is hereby appointed as an Independent Director of the Company to hold office for five consecutive years for a term up to 08th April, 2020."
"RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, any of the Director of the Company be and is hereby severally authorized to do all such acts, deeds and things as it may be deemed necessary in this regard, including filing of necessary statutory forms with Registrar of Companies, Ministry of Corporate Affairs, as may be required from time to time".
6. Appointment of Ms. Komal Jajodia (DIN: 05186391) as an Independent Director.
To consider and if thought fit, to pass with or without modification, the following resolution as an Ordinary Resolution:
"RESOLVED that pursuant to the provisions of Sections 149, 150, 152 and any other applicable provisions of the Companies Act, 2013 (the "Act") and the Companies Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) read with Schedule IV to the Act and Clause 49 of the Listing Agreement, Ms. Komal Jajodia (DIN: 05186391), who was appointed as an Additional Director of the Company by the Board of Directors with effect from 06th May, 2015, in terms of Section 161(1) of the Act and whose term of office expires at the Annual General Meeting and in respect of whom the Company has received a notice in writing from a member proposing his candidature for the office of Director, be and is hereby appointed as an Independent Director of the Company to hold office for five consecutive years for a term up to 05th May, 2020."
"RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, any of the Director of the Company be and is hereby severally authorized to do all such acts, deeds and things as it may be deemed necessary in this regard, including filing of necessary statutory forms with Registrar of Companies, Ministry of Corporate Affairs, as may be required from time to time".
7. Re-Designate Mr. Manoj Jain as Whole-time Director
To consider and if thought fit, to pass with or without modification, the following resolution as an Ordinary Resolution:
"RESOLVED THAT pursuant to recommendation of the Nomination and Compensation Committee, and approval of the Board and subject to the provisions of Sections 196, 197, 198, 203 and other applicable provisions of the Companies Act, 2013 and the rules made thereunder (including any statutory modification or re-enactment thereof) read with Schedule- V of the Companies Act, 2013 and Articles of Association of the Company, approval of the members of the Company be and is hereby accorded to re-designate Mr. Manoj Jain, as Whole-time Director of the Company with effect from August 05, 2015 to August 04, 2020, as well as the payment of salary, commission and perquisites (hereinafter referred to as "remuneration"), upon the terms and conditions as detailed in the explanatory statement attached hereto, which is hereby approved and sanctioned with authority to the Board of Directors to alter and vary the terms and conditions of the said re-appointment and / or agreement in such manner as may be agreed to between the Board of Directors and Mr. Manoj Jain.
RESOLVED FURTHER THAT the remuneration payable to Mr. Manoj Jain, shall not exceed the overall ceiling of the total managerial remuneration as provided under Section 197 of the Companies Act, 2013 or such other limits as may be prescribed from time to time.
RESOLVED FURTHER THAT the Board be and is hereby authorized to do all such acts, deeds and things and execute all such documents, instruments and writings as may be required and to delegate all or any of its powers herein conferred to any Committee of Directors or Director(s) to give effect to the aforesaid resolution.
8. Ratification for the relevant date mentioned in notice of postal ballot dated June 09, 2015
To consider and if thought fit, to pass with or without modification, the following resolution as an Ordinary Resolution:
"RESOLVED THAT the Relevant Date as per SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 was erroneously mentioned as 22-June-2015 in the Notice of Postal ballot of the Company dated June 9, 2015, which is be and now hereby ratified as 23-June-2015.
RESOLVED FURTHER THAT the Board of the Company be and are hereby authorized the mention correct relevant date with effect from June 9, 2015 on all the filings, Documents in connection with the issue of warrants of the Company.
By Order of the Board For Avon Lifesciences Limited
(Formerly known as Avon Organics Ltd)Sd/-
Jignesh PatelPlace: Mumbai Company SecretaryDate: 04.09.2015
NOTES1. The relative Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 ("Act") in respect of the
business under Item Nos. 4 to 7 of the Notice, is annexed hereto. The relevant details as required under Clause 49 of the Listing Agreements entered into with the Stock Exchanges, of persons seeking appointment / re-appointment as Directors, are also annexed.
2. A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER. Proxies, in order to be effective, must be received at the Company's Corporate Office situated at 4th Floor, H Wing, Tex Centre, Chandivali, off. Saki Vihar Road , Andheri (E), Mumbai 400 072 not less than 48 hours before the meeting. Proxies submitted on behalf of companies, societies, partnership firms, etc. must be supported by appropriate resolution/authority, as applicable, issued on behalf of the nominating organisation.
Members are requested to note that a person can act as a proxy on behalf of Members not exceeding 50 and holding in the aggregate not more than 10% of the total share capital of the Company carrying voting rights. In case a proxy is proposed to be appointed by a Member holding more than 10% of the total share capital of the Company carrying voting rights, then such proxy shall not act as a proxy for any other person or shareholder.
3. Corporate Members intending to send their authorised representatives to attend the Annual General Meeting (AGM) are requested to send a certified copy of the Board Resolution authorising their representative to attend and vote in their behalf at the Meeting.
4. In case of joint holders attending the Meeting, only such joint holder who is higher in the order of names will be entitled to vote.
5. Only bonafide members of the Company whose names appear on the Register of Members/Proxy holders, in possession of valid attendance slips duly filled and signed will be permitted to attend the meeting. The Company
Avon Lifesciences Ltd
54
22nd ANNUAL REPORT
reserves its right to take all steps as may be deemed necessary to restrict non-members from attending the meeting.
6. Members are requested to bring their copies of Annual Report to the Meeting. In order to enable us to register your attendance at the venue of the Annual General Meeting, we request you to please bring your folio number/demat account number/DP ID-Client ID to enable us to give you a duly filled attendance slip for your signature and participation at the meeting.
7. The Register of Members and the Transfer Books of the Company will remain closed from Thursday, 24th September, 2015 to Wednesday, 30th September, 2015, both days inclusive.
8. The Notice of the AGM along with the Annual Report 2014-15 is being sent by electronic mode to those Members whose e-mail addresses are registered with the Company/Depositories, unless any Member has requested for a physical copy of the same. For Members who have not registered their e-mail addresses, physical copies are being sent by the permitted mode.
9. To support the 'Green Initiative', the Members who have not registered their e-mail addresses are requested to register the same with RTA/Depositories.
10. Voting through Electronic Means
I. In compliance with the provisions of Section 108 of the Act and the Rules framed thereunder, the Members are provided with the facility to cast their vote electronically through the e-voting services provided by Central Depository Services Limited (CDSL), on all resolutions set forth in this Notice.
II. Mr. Aashit Doshi, Company Secretary in Practice (Membership No. 28415, Certificate of Practice No. 10190), Mumbai has been appointed as the Scrutinizer to scrutinize the e-voting process(including the Physical Assent/ Dissent Form received from Members who do not have access to e-voting) in fair and transparent manner.
III. The facility for voting, either through electronic voting system or ballot or polling paper shall also be made available at the meeting and Members attending the meeting who have not already cast their vote by remote e-voting or by ballot form shall be able to exercise their right at the meeting.
IV. The Members who have cast their vote by remote e-voting or by ballot form prior to the meeting may also attend the meeting but shall not be entitled to cast their vote again.
V. Members can opt for only one mode of voting, i.e., either by Ballot Form or e-voting. In case Members cast their votes through both the modes, voting done by e-voting shall prevail and votes cast through Ballot Form shall be treated as invalid.
VI. In case of those members who do not have access to e-voting facility, they can use the assent/dissent form sent herewith and convey their assent/dissent to each one of the items of business to be transacted at the ensuing AGM and send the form in a sealed envelope to reach Mr. Aashit Doshi, Scrutinizer appointed by the Company at the Corporate Office of the Company at 4th Floor, H Wing, Tex Centre, Chandivali, off. Saki Vihar Road , Andheri (E), Mumbai 400 072 on or before Tuesday, 29th September, 2015 at (05.00 P.M.).
VII. Members who have not registered their e-mail addresses, so far are requested to register their e-mail addresses with the Depository. Members who hold shares in physical form are requested to register their e-mail addresses with the Registrar & Share Transfer Agent (RTA), M/s. XL Softech Systems Limited, 3, Sagar Soceity,Rd No.2, Banjara Hills, Hyderabad- 500034, Telangana.
The instructions for shareholders voting electronically are as under:
i. The voting period begins on September 27, 2015 at 9.00am and ends on September 29, 2015 at 5.00pm. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of September 23, 2015, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
ii. The shareholders should log on to the e-voting website www.evotingindia.com.
iii. Click on Shareholders.
iv. Now Enter your User ID
a. For CDSL: 16 digits beneficiary ID
b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID
c. Members holding shares in Physical Form should enter Folio Number registered with the Company.
v. Next enter the Image Verification as displayed and Click on Login.
vi. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier
For Members holding shares in Demat Form and Physical Form
PAN Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)• Members who have not updated their PAN with the Company/Depository Participant are
requested to use the sequence number which is printed on Postal Ballot / Attendance Slip indicated in the PAN field.
DOB Enter the Date of Birth as recorded in your demat account or in the company records for the said demat account or folio in dd/mm/yyyy format.
voting of any company, then your existing password is to be used.
VII. If you are a first time user follow the steps given below:
VIII. After entering these details appropriately, click on “SUBMIT” tab.
IX. Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
X. For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
XI. Click on the EVSN for the relevant AVON ORGANICS LTD (AVON LIFESCIENCES LIMITED) on which you choose to vote.
XII. On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
XIII. Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
XIV. After selecting the resolution you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
XV. Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
XVI. You can also take out print of the voting done by you by clicking on “Click here to print” option on the Voting page.
XVII. If Demat account holder has forgotten the same password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
XVIII. Note for Non – Individual Shareholders and Custodians
• Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodian are required to log on to www.evotingindia.com and register themselves as Corporates.
• A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to [email protected].
• After receiving the login details a compliance user should be created using the admin login and password. The Compliance user would be able to link the account(s) for which they wish to vote on.
• The list of accounts should be mailed to [email protected] and on approval of the accounts they would be able to cast their vote.
• A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
XIX. In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions (“FAQs”) and e-voting manual available at www.evotingindia.com, under help section or write an email to [email protected].
Avon Lifesciences Ltd
76
22nd ANNUAL REPORT
EXPLANATORY STATEMENTAs required by Section 102 of the Companies Act, 2013 (“Act”), the following explanatory statement sets out all material facts relating to the business mentioned under Item Nos. 4 to 7 of the accompanying Notice:
Item No. 4
This explanatory statement is provided though strictly not required as per Section 102 of the Act.
M/s. Mukesh Mehta & Associates, Chartered Accountants (Registration No. 116309W), were appointed as the statutory auditors of the Company for a period of three years at the Annual General Meeting (AGM) of the Company held on December 30, 2014. As per provisions of Section 139(1) of the Act, their appointment for the above tenure is subject to ratification by members at every AGM. Accordingly, ratification of the members is being sought for the proposal contained in the Resolution set out at item no. 4 of the Notice.
The Board commends the Resolution at Item No. 4 for approval by the Members.
None of the Directors or Key Managerial Personnel (KMP) or relatives of Directors and KMPs is concerned or interested in the Resolution at Item No. 4 of the accompanying Notice.
Item No. 5
The Board of Directors of the Company appointed Ms. Zeenat Pathan (DIN: 07153363), as an Additional Director of the Company, in the category of Independent Directors. As per the provisions of Section 161(1) of the Act, she holds office of Additional Director only up to the date of the forthcoming Annual General Meeting of the Company, and is eligible for appointment as Director.
Ms. Zeenat Pathan has given a declaration to the Board that she meets the criteria of independence as provided under Section 149(6) of the Act.
The Company has received a notice under Section 160 of the Act proposing her candidature for the office of Director of the Company, along with the requisite deposit. It proposed to appoint her as an Independent Director of the Company to hold office for five consecutive years for a term up to 08th April, 2020.
Board recommends the resolution for the approval of members as Ordinary Resolution.
None of the Directors and/or Key Managerial Personnel of the Company or their relatives, except Ms. Zeenat Pathan (whose appointment is proposed in this resolution) are in any way concerned or interested in the resolution
Item No. 6
The Board of Directors of the Company appointed Ms. Komal Jajodia (DIN: 05186391), as an Additional Director of the Company, in the category of Independent Directors. As per the provisions of Section 161(1) of the Act, she holds office of Additional Director only up to the date of the forthcoming Annual General Meeting of the Company, and is eligible for appointment as Director.
Ms. Komal Jajodia has given a declaration to the Board that she meets the criteria of independence as provided under Section 149(6) of the Act.
The Company has received a notice under Section 160 of the Act proposing her candidature for the office of Director of the Company, along with the requisite deposit. It proposed to appoint her as an Independent Director of the Company to hold office for five consecutive years for a term up to 05th May, 2020.
Board recommends the resolution for the approval of members as Ordinary Resolution.
None of the Directors and/or Key Managerial Personnel of the Company or their relatives, except Ms. Komal Jajodia (whose appointment is proposed in this resolution) are in any way concerned or interested in the resolution
Item No. 7
Pursuant to the recommendation of the Nomination and Compensation Committee the Board of Directors of the Company vide resolution passed on August 5, 2015 approved to re-designate Mr. Manoj Jain as Whole Time Director in accordance with the provisions contained in Section 196 and 197 read with Section 203 of the Companies Act, 2013.
Approval of the members is required by way of Ordinary Resolution for appointment and payment of remuneration. This explanatory statement may also be read and treated as disclosure in compliance with the requirements of Section 190 of the Companies Act, 2013.
The details of remuneration payable to Mr. Manoj Jain (at inadequate profits with the Company) and the terms and conditions of the appointment are given below:
a) Period of Appointment : 5 (Five) years effective from August 05, 2015 upto August 04, 2020
b) Remuneration : Rs. 1,50,000/-p.m.
with authority to the Board/ Nomination and Compensation Committee constituted by the Board to re-fix his salary from time to time within the aforesaid period, keeping into view his performance and the ceilings, if any, fixed by statute, subject to Shareholders' approval after such enhancement /re-fixation by the board.
The following perquisites are included in the abovementioned salary:
a) Medical reimbursement: Actual expenses incurred for self.
b) Contribution to Provident Fund, Superannuation fund or Annuity Fund will not be included in the computation of the ceiling on perquisites to the extent that these either singly or put together are not taxable under the Income Tax Act, 1961.
c) Gratuity payable shall be calculated as per the provisions of Gratuity Act, 1972.
d) Encashment of Leave at the end of the tenure will not be included in the computation of the ceiling on perquisites.
As the terms of appointment and the remuneration proposed are in conformity with the relevant provisions of the Companies Act, 2013, read with Schedule V to the said Act, Central Government approval is not necessary for this appointment.
Notice has been received from member signifying their intention to propose appointment of Mr. Manoj Jain as Whole Time Director of the Company along with a deposit of Rs. 1,00,000.
Mr. Manoj Jain may be deemed to be concerned or interested in the said resolution. No other Director, key managerial personnel or their relatives are concerned or interested in the said resolution.
By Order of the Board For Avon Lifesciences Limited
(Formerly known as Avon Organics Ltd)Sd/-
Jignesh Patel
Place: Mumbai Company SecretaryDate: 04.09.2015
Directors' Report
Dear Shareholders,
Your Directors have pleasure in presenting their report on the business operations and accounts of the Company for the ndYear ended 31st March, 2015 along with 22 Annual Report.
FINANCIAL SUMMARY /PERFORMANCE OF THE COMPANY
(Amt Rs in Lacs)
DIVIDEND
In view of loss incurred during the year under review, your Directors do not recommend any divided on Equity Shares.
OPERATIONAL REVIEW
The Company's performance deteriorated owing to sluggish external factors and various issues at the customers end beyond the control of the Management. The Total income was down from Rs. 5707.04 Lacs to Rs. 2911.48 Lacs during the period of review.
Accordingly due to above factors the Loss after Tax Stood at Rs. 3025.65 Lacs as against Rs. 3257.34 Lacs during the last financial period of review.
The Company continues to operate only in one segment i.e. pharmaceuticals and there is no change in the nature of business of the Company.
There are no material changes and commitments affecting the financial position of the Company, which have occurred between the end of the financial year of the Company and the date of this report.
No significant or material orders passed or have been passed against the Company by the regulators, courts, or tribunals, which impacts the going concern status and Company's operations in future.
SHARE CAPITAL
During the year under review, there was no change in the share capital structure and the paid up capital of the Company as ston 31 March, 2015 stood at Rs. 2,250.00 Lacs
UPDATES
The Company on August 12, 2015 has allotted 1,05,00,000 (One Crore Five Lacs) Warrants convertible into equal number of equity shares of Rs.10/- each at an issue price of Rs.26/- each (including premium of Rs.16/- each) on preferential basis to non promoters, pursuant to Special Resolution passed through Postal Ballot and in compliance with various laws applicable for such Preferential issue.
Pursuant to the Special Resolution passed through Postal Ballot and the approval received from the Ministry of Corporate Affairs through the Registrar of Companies, Hyderabad, the name of Company has been changed from AVON ORGANICS LIMITED to “AVON LIFESCIENCES LIMITED” w.e.f. August 14, 2015.
The Management believes that the business potential and fundamentals of the Company remains robust. The Management is diligently pursuing every opportunity to recover from the losses incurred and is confident of better times ahead.
Avon Lifesciences Ltd
98
22nd ANNUAL REPORT
Particulars forYear ended 31st March
2015 2014
Total Income 2,911.48 5,707.04
EBITDA (939.77) (427.05)
Profit/ (Loss) before Tax (3,279.36) (3,202.91)
Profit/ (Loss) after Tax (3,025.60) (3,257.34)
Earnings / (Loss) Per Share (EPS) (13.48) (14.48)
MANAGEMENT DISCUSSION AND ANALYSIS
A detailed Management Discussion and Analysis forms part of this annual report, which is given elsewhere in the Report.
DIRECTORS
a. Board of Directors
Mr. Ajit Kamath (DIN: 00032799), retires by rotation at the ensuing Annual General Meeting and being eligible, offers himself for re-appointment.
Mr. Rajendra Kaimal (DIN: 00032839), retires by rotation at the ensuing Annual General Meeting and being eligible, offers himself for re-appointment.
Ms. Zeenat Pathan (DIN: 07153363), was appointed as an Additional Director (Woman Director) on the Board of the Company, in the category of Non –Executive, Independent Director. Pursuant to Section 161(1) of the Companies Act, 2013, Ms. Zeenat Pathan holds office till the date of this Annual General Meeting and it is proposed to appoint her as Non –Executive, Independent Director of the Company for the period of 5 years for a term up to April 08, 2020.
Ms. Komal Jajodia (DIN: 05186391), was appointed as an Additional Director on the Board of the Company, in the category of Non –Executive, Independent Director. Pursuant to Section 161(1) of the Companies Act, 2013, Ms. Zeenat Pathan holds office till the date of this Annual General Meeting and it is proposed to appoint her as Non –Executive, Independent Director of the Company for the period of 5 years for a term up to May 05, 2020.
Brief profiles of the abovementioned Directors are included in a separate “Annexure B” after the Notice, forming part of this Annual Report.
b. Board meetings
During the year, 10 Board meetings were held, with gap between Meetings not exceeding the period prescribed under the Act. Details of Board and Board committee meetings held during the year are given in the Corporate Governance Report. Board meeting dates are finalised in consultation with all directors and agenda papers backed up by comprehensive notes and detailed background information are circulated well in advance before the date of the meeting thereby enabling the Board to take informed decisions. The Board is also apprised of updates, important developments in industry, segments, business operations, marketing, products etc.
c. Independent Director's familiarisation Programme
As required by the Listing Agreement, the Company has in place director's familiarization programme for Independent Directors in order to familiarise them with business model, management structure, Industry overview, manufacturing operations, internal control system and processes, risk management framework, functioning of various divisions, HR Management etc.
d. Evaluation of Board, Committees and Directors
Pursuant to the provisions of the Companies Act, 2013 and Clause 49 of the Listing Agreement, the Remuneration and Nomination Committee has laid down the criteria for performance evaluation of Board of Directors (Including Independent Directors), Key Managerial Personnel (KMPs) and Committees of the Board on the basis of which they have been evaluated.
e. Policy on appointment and remuneration of Directors
The Company has formulated criteria for determining Qualifications, Abilities, Experience and Independence of a Director as also a Policy for remuneration of Directors, Key managerial Personnel and senior management. The details of criteria laid down and the Remuneration Policy are given in the Corporate Governance Report.
AUDITORS
a. Statutory Auditors
Pursuant to the provisions of Section 139 of the Act and the rules framed thereunder, M/s. Mukesh Mehta & Associates, Chartered Accountants (Registration No. 116309W), were appointed as statutory auditors of the Company from the conclusion of the twenty-first annual general meeting (AGM) of the Company held on December 30, 2014 till the conclusion of the twenty-forth AGM to be held in the year 2017, subject to ratification of their appointment at every AGM.
b. Statutory Auditors Report
The remarks as contained in the Auditor's Report read with Notes forming part of the accounts are self-explanatory.
a. Secretarial Auditors
Pursuant to the provisions of Section 204 of the Act and the Companies (Appointment and Remuneration of Managerial
Avon Lifesciences Ltd
1110
22nd ANNUAL REPORT
Personnel) Rules, 2014, the Company has appointed Ms. Ashwini Rajeshirke, Company Secretary in Practice to undertake the Secretarial Audit of the Company. The Secretarial Audit Report is annexed herewith as “Annexure C”.
INTERNAL CONTROL SYSTEM AND COMPLIANCE FRAMEWORK
The Company has an Internal Control System, commensurate with size, scale and complexity of its operations. The internal financial controls are adequate and are operating effectively so as to ensure orderly and efficient conduct of business operations. The Audit Committee formulates the scope, functioning, periodicity and methodology for conducting the audit.
The Board has also put in place requisite legal compliance framework to ensure compliance of all the applicable laws and that such systems are adequate and operating effectively.
VIGIL MECHANISM
The Company has set up vigil mechanism viz. Whistle Blower Policy to enable the employees and Directors to report genuine concerns and irregularities, if any in the Company, noticed by them. The same is reviewed by the Audit Committee from time to time.
RISK MANAGEMENT POLICY
During the year, your Directors have constituted a Risk Management Committee and has formulated a Risk Management Policy which aims at enhancing shareholders' value and providing an optimum risk reward tradeoff. The risk management approach is based on a clear understanding of the variety of risks that the organization faces, disciplined risk monitoring and measurement and continuous risk assessment and mitigation measures.
RELATED PARTY TRANSACTIONS
All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business. There are no materially significant related party transactions made by the Company which may have a potential conflict with the interest of the Company at large and thus disclosure in Form AOC-2 is not required.
None of the Non-Executive Directors has any pecuniary relationship or transactions with the Company other than sitting fees payable (if any) to them.
MANAGERIAL REMUNERATION AND PARTICULARS OF EMPLOYEES
Information on particulars of employees' remuneration as per Section 197 of the Companies Act, 2013, read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is reported to be nil as there are no employees who are in receipt of remuneration above the prescribed limit.
The ratio of remuneration of each director to the median employee's remuneration and other details in terms of Sub - Section 12 of Section 197 of the Companies Act, 2013 read with Rule 5 (1) of the Companies Appointment and Remuneration of Managerial Personnel) Rules, 2014, are not applicable as the Directors did not draw and remuneration from the Company for the Financial Year 2014-15 and The Board of Directors appointed Mr. Jignesh Patel as Company Secretary during the financial year 2014-15 only.
RECONCILIATION OF SHARE CAPITAL AUDIT
As directed by the Securities and Exchange Board of India (SEBI), Reconciliation of Share Capital Audit has been carried out at the specified period, by a Practicing Company Secretary.
LOANS, GUARANTEES OR INVESTMENTS
Details of Loans, Guarantees and Investments, if any covered under the provisions of Section 186 of the Act are given in the notes to the Financial Statements.
CORPORATE SOCIAL RESPONSIBILITY (CSR)
Pursuant to the provisions of section 135 of the Act, read with CSR Rules, a CSR committee of the Company is in the process of formulating appropriate CSR policy. However due to losses incurred by the Company in this and previous financial year the Company did not undertake any CSR activity.
DEPOSITS
Your Company has not accepted any deposits from the public falling within the purview of Section 73 of the Act, read with the Companies (Acceptance of Deposits) Rules, 2014.
EXTRACT OF THE ANNUAL RETURN
The extract of the Annual Return in form MGT 9 is annexed herewith as “Annexure D”.
DIRECTORS' RESPONSIBILITY STATEMENT
To the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors confirm:
a. that in the preparation of the annual accounts for the year ended 31st March 2015, the applicable Accounting Standards had been followed along with proper explanation relating to material departures, if any;
b. that the directors had selected accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year ended 31st March 2015 and of the profit of the Company for that period;
c. that proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
d. that the annual accounts/financial statements have been prepared on a going concern basis;
e. that proper internal financial controls were in place and that the financial controls were adequate and were operating effectively;
f. that the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.
CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO
The information relating to Conservation of energy, technology absorption, foreign exchange earnings and outgo, pursuant to Section 134 of the Act, read with the Companies (Accounts) Rules, 2014 is given as “Annexure A” and forms part of this report.
CORPORATE GOVERNANCE
Report on Corporate Governance is given elsewhere in this Annual Report. Certificate from the Auditors regarding compliance of conditions of Corporate Governance as stipulated in Clause 49 of the Listing Agreement with Stock Exchanges is also appended to the report on Corporate Governance.
GRATITUDE & ACKNOWLEDGMENTS
Your Directors place on record their sincere thanks to bankers, business associates, consultants, and various Government Authorities for their continued support extended to your Companies activities during the year under review. Your Directors deeply appreciate the committed efforts put in by employees at all levels. Your Directors also acknowledges gratefully the shareholders for their support and confidence reposed on your Company.
For and on behalf of the Board of Directors
Avon Lifesciences Limited
(formerly known as Avon Organics Ltd)
Ajit Kamath
Chairman
DIN: 00032799
Date: 04.09.2015
Place: Mumbai
Avon Lifesciences Ltd
1312
22nd ANNUAL REPORT
Annexure A - TO THE DIRECTORS' REPORT
Information under Section 217(1) (e) of the Companies Act, 1956 read with the Companies (Disclosure of Particulars in the Report of the Board of Directors) Rules, 1988
A. Conservation of Energy :
a. Energy Conservation Measures taken:The Company is engaged in continuous process of energy conservation through improved operational and maintenance practices. The Company is also undertaking feasibility study for using LED lights at work place.
b. Total energy consumption per unit of Production:Details are furnished in Form A
FORM A
Form for disclosure of particulars with respect to conservation of energy.
B. Technology absorption : Details are furnished in Form B
FORM B
I RESEARCH AND DEVELOPMENT :
1. Specific areas in which R & D was carried out.
The Company continued its research on CEFDINIR intermediate, which is ready to be implemented at the plant for commercial quantities.
2. Benefits derived from above R & D.
There would be considerable cost advantage on the manufacture of CEFDINIR intermediate in commercial quantities.
3. Future plan of action.
To achieve increased production of DEAA (Diethyl aceto acetamide) and CEFDINIR intermediate and to evaluate possibilities of adding products.
4. Expenditure on R & D :
Year ended 31st March 2015 2014
Electricity
(i) Power and fuel consumption Electricity (a) Purchased Unit (KWH)
120,760.00 KWH 448,720.00 KWH
TOTAL Amount (Rs) 1,050,714.00 4,585,423.00
Rate/Unit (KWH) (Rs) 8.70 10.21
Diesel
(b) Own generation Unit (KWH) 1185 KWH 2202 KWH
Cost / Unit (KWH) (Rs) 24.08 23.24
TOTAL Amount (Rs) 28534.05 51174.90
Coal
(b) Own generation Unit (KWH) - -
Unit per Ltr. of Diesel Oil (KWH) - -
Cost / Unit (KWH) (Rs) - -
Particulars Amount (Rs in Lacs)
Capital Expenditure NIL
Recurring Expenditure NIL
TOTAL NIL
Total R&D expenditure as a percentage of total turnover NIL
C. Foreign Exchange Earnings and Outgo 2014-2015 2013-2014
1. Foreign Exchange Earnings (Rs. In Lacs) 1831.99 198.79
3. Net Foreign Exchange Earnings (outgo) (Rs. In Lacs) 663.92 (793.74)
1. Efforts in brief made towards technology absorption
: Consistent efforts made towards achieving the required quality of Pseudoephedrine Hydrochloride.
2. Benefits derived as a result of the above
efforts, e.g. product improvement, cost reduction, product development, import substitution etc.
: Cost reduction in Pseudoephedrine Hydrochloride.
3. In case of imported technology ( import during the last 5 years reckoned from the beginning of the year); following information may be furnished a Technology imported b Year of import c Has technology been fully
absorbed
Nil Not Applicable Not Applicable
II TECHNOLOGY ABSORPTION :
An
nexu
re B
- D
eta
ils o
f D
irecto
rs s
eekin
g a
pp
oin
tmen
t/re
ap
po
intm
en
t in
fo
rth
co
min
g A
nn
ual
Gen
era
l M
eeti
ng
:
Na
me
Mr. M
anoj J
ain
Mr. R
aje
nd
ra K
aim
al
Mr. A
jit K
am
ath
Ms.
Ze
en
at
Path
an
Ms.
Kom
al J
ajo
dia
Date
of B
irth
20.0
3.1
970
23.0
6.1
97
31
2.1
2.1
96
90
5.1
2.1
98
631.0
5.1
987
Da
te o
f A
ppoin
tment
31.0
1.2
009
30.0
5.2
01
33
1.0
1.2
00
90
9.0
4.2
01
506.0
5.2
015
Na
tionalit
yIn
dia
nIn
dia
nIn
dia
nIn
dia
nIn
dia
n
Cate
gory
Pro
mote
rP
rom
ote
rP
rom
ote
rIn
de
pe
nd
ent
& N
on
Exe
cutiv
e D
irect
or
Independent
& N
on
Exe
cutiv
e D
irect
or
Desi
gnatio
nW
hole
Tim
e D
irect
or
Non
Exe
cutiv
e D
ire
cto
rC
ha
irm
an
& N
on
Exe
cutiv
e
Dire
cto
rIn
de
pe
nd
ent
& N
on
Exe
cutiv
e D
irect
or
Independent
& N
on
Exe
cutiv
e D
irect
or
Qu
alif
icatio
n /
Exp
ert
ise in
Speci
fic
Funct
ional A
reas
Mr. M
anoj J
ain
, aged 4
5 y
ears
, hold
s a B
ach
elo
r's
Degre
e in
C
om
merc
e.
He is
a C
hart
ere
d
Acc
ounta
nt
by
qualif
icatio
n a
nd
has
more
than 1
7 y
ears
of
exp
erience
in t
he p
harm
ace
utic
al
indust
ry.
He o
vers
eas
the d
ay
to
day
funct
ionin
g o
f th
e c
om
pany.
H
e is
resp
onsi
ble
for
Acc
ountin
g,
Auditi
ng, Ta
xatio
n a
nd
Form
ula
ting o
f C
orp
ora
te
Polic
ies.
Mr. R
aje
nd
ra K
aim
al, a
ge
d 4
1
years
, h
old
s a
Ba
che
lors
De
gre
e
in C
om
me
rce
fro
m th
e U
niv
ers
ity
of
Mu
mb
ai.
He
ha
s co
mp
lete
d
his
Ma
ste
rs in
Ma
na
ge
me
nt
Stu
die
s fr
om
Na
rse
e M
on
jee
In
stitu
te o
f M
an
ag
em
en
t S
tud
ies,
M
um
ba
i an
d is
a C
ost
A
cco
un
tan
t fr
om
th
e In
stitu
te o
f C
ost
an
d W
ork
s A
cco
un
tan
ts o
f In
dia
. H
e h
as
ove
r 1
4 y
ea
rs o
f exp
erie
nce
in th
e p
ha
rma
ceu
tica
l in
dust
ry.
Mr. A
jit K
am
ath
, a
ge
d 4
4 y
ea
rs,
ho
lds
aB
ach
elo
r's
de
gre
e in
Co
mm
erc
e
fro
m U
niv
ers
ity o
f M
um
ba
i. H
e
ha
s m
ore
th
an
16
ye
ars
of
exp
erie
nce
in th
e p
ha
rma
ceu
tica
l in
du
stry
. H
e h
as
be
en
invo
lve
d
an
d in
stru
me
nta
l in
pla
nn
ing
an
d
form
ula
ting
th
e o
vera
ll b
usi
ne
ss
stra
teg
y a
nd
de
velo
pin
g
bu
sin
ess
re
latio
ns
for
ou
r C
om
pa
ny.
Ms.
Ze
en
at P
ath
an,
ag
ed
29
, ye
ars
, h
old
s, B
ach
elo
rs
De
gre
e in
C
om
me
rce
fro
m t
he
Un
ive
rsity
of
Mu
mb
ai.
Ms.
Kom
al J
ajo
dia
, aged 2
9 y
ears
, hold
s M
ast
ers
D
egre
e in
C
om
merc
e f
rom
the
Univ
ers
ity o
f M
um
bai a
nd a
lso a
C
hart
ere
d
Acc
ounta
nt
(CA
).
She h
as
good
exp
erience
in t
he
Taxa
tion a
nd
Acc
ounts
.
Occ
upatio
nS
erv
ice
Serv
ice
Se
rvic
eS
erv
ice
Serv
ice
Oth
er
Direct
ors
hip
s/
Direct
ors
hip
s held
in
oth
er
com
panie
s
• A
rch P
harm
ala
bs
Lim
ited
• R
ivers
ide F
arm
land P
riva
te
Lim
ited
• R
ivert
ouch
Farm
land P
riva
te
Lim
ited
• R
iverv
iew
Realty
Priva
te
Lim
ited
• A
rch P
harm
ala
bs
FZ
-LLC
(UA
E)
• R
egal P
harm
a P
te.
Ltd
.,
(S
ingapore
)
• A
rch
Ph
arm
ach
em
Ltd
• A
rch
Im
pe
x P
riva
te L
imite
d•
Arc
h P
ha
rma
lab
s L
imite
d•
Arc
h L
ife S
cie
nce
s L
imite
d•
A M
R In
vest
me
nts
Priva
te
Lim
ited
• A
rch
Fin
ech
em
ica
ls L
imite
d•
Arc
h In
fra
Ve
ntu
res
Lim
ited
• A
mra
Re
me
die
s L
imite
d•
Arc
h A
gro
In
du
strie
s P
riva
te
Lim
ited
• A
mra
Re
na
l Ca
re L
imite
d•
Arc
h In
vest
me
nt P
riva
te
Lim
ited
• A
rch
He
rba
ls P
riva
te L
imite
d•
Arc
h P
ha
rma
lab
s F
Z-L
LC
(UA
E)
• A
rch
In
vest
me
nt
Priva
te L
imite
d•
Arc
h H
erb
als
Priva
te L
imite
d•
Arc
h I
mp
ex
Priva
te L
imite
d•
Arc
h P
ha
rma
che
m L
td•
Arc
h P
ha
rma
lab
s L
imite
d•
Ma
rm R
ea
lty P
riva
te L
imite
d•
Arc
h L
ife S
cie
nce
s L
imite
d•
A M
R I
nve
stm
en
ts P
riva
te
Lim
ited
• A
rch
Fin
ech
em
ica
ls L
imite
d•
Arc
h I
nfr
a V
en
ture
s L
imite
d•
Am
ra R
em
ed
ies
Lim
ited
• A
rch
Ag
ro I
nd
ust
rie
s P
riva
te
L
imite
d•
Am
ra R
en
al C
are
Lim
ited
• R
eg
al P
ha
rma
Pte
. L
td.
(S
ing
ap
ore
)•
Arc
h P
ha
rma
lab
s F
Z-L
LC
(U
AE
)
N.a
Prim
e C
orp
ora
te
Managem
ent
Consu
lting P
riva
te
Lim
ited
Sh
are
hold
ing in
the
Com
pany
NIL
NIL
NIL
NIL
NIL
Re
latio
nsh
ip b
etw
een
direct
ors
inte
r-se
NIL
NIL
NIL
NIL
NIL
Avon Lifesciences Ltd
1514
22nd ANNUAL REPORT
:
Annexure C - SECRETARIAL AUDIT REPORT
For the Financial Year Ended March 31, 2015
[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]
To,
The Members,
Avon Lifesciences Limited
(Formerly known as Avon Organics Limited)
Survey No.18, Yawapur Village, Sadasivpet Mandal,
Medak Dist Rict, Andhra Padesh - 502291.
I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by AVON LIFESCIENCES LIMITED (Formerly known as AVON ORGANICS LIMITED) (hereinafter called as “the Company”). The Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.
Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on March 31, 2015, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:
I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2015 according to the provisions of:
(i) The Companies Act, 2013 (the Act) and the rules made there under; which have been notified and the Companies Act, 1956 (to the extend applicable);
(ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
(iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment;
(v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
(a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
(b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
(c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
(d) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
(vi) Other laws applicable to the Company as per the representations made by the Management.
I have also examined compliance with the applicable clauses of the following:
(I) Secretarial Standards issued by The Institute of Company Secretaries of India with respect to board and general meetings were yet to be specified under the Act by the Institute during the audit period.
(ii) The Listing Agreements entered into by the Company with BSE Limited;
During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to the following observation:
1. During the audit period, the Company has not submitted the Annual Performance Report (APR) pursuant to Regulation 15 of Foreign Exchange Management (Transfer or Issue of any Foreign Security) Regulations, 2004.
2. During the audit period under review, the Company is not regular in depositing the undisputed statutory
dues including provident fund, Employees' State Insurance, Income Tax, Sales Tax, Wealth Tax, Customs duty, Excise-duty, Service Tax, Cess and any other Statutory dues with appropriate authorities as per the Auditor's report.
3. During the year, the Company has not appointed Woman Director on the Board pursuant to Section 149 of the Companies Act, 2013 and Clause 49 of Listing Agreement. However, on April 9, 2015 Company has appointed Ms. Zeenat Sayeed Pathan as Woman director on the Board.
4. Official Website of Company was not fully functional during the audit period. However, the Company is in process of updating the same.
5. The Company has not complied with the provision of Section 148 of Companies Act, 2013 read with rules framed there under and has not filed FORM-I for filing of Cost Audit Report with Central Government for the year ended March 31, 2014 pursuant to Section 233B of Companies Act, 1956. However the management has assured that all such filings will be done in due course.
I further report that:
The Board of Directors of the Company is duly constituted. However, the during audit period there were improper balances of Executive Directors, Non-Executive Directors and Independent Directors in the Company. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.
I further report that as per the explanations given to us and the representations made by the Management and relied upon by us there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
I further report that during the audit period the Company had the following events in pursuance of the above referred laws, rules, regulations, guidelines etc.:
1. The Board has given approval for Issue of Shares on Preferential basis; to increase Authorised Capital of the Company; Shifting of the registered office of the company through postal ballot process. However, due to some unavoidable reasons the process of Postal Ballot had been postponed by the Company, which was duly intimated to the Exchange.
2. Approval of Shareholders for increase in borrowing limits upto Rs. 1,000 Crore in pursuance to Section 180 (1) (c) of the Companies Act, 2013 read with rules framed there under.
3. Approval of Shareholders for authorizing to mortgage the assets of the Company upto limit of Rs. 1,000 Crore under Section 180(1)(a) of the Act.
Sd/-.
Ashwini Rajeshirke
Practising Company Secretary
ACS No.: 26223
C P No.: 9746
Place: Mumbai
Date: 03.09.2015
This Report is to be read with our letter of even date which is annexed as Annexure 1 and Forms an integral part of this report.
Annexure 1
To,
The Members,
Avon Lifesciences Limited
(Formerly known as Avon Organics Limited)
Survey No.18, Yawapur Village, Sadasivpet Mandal,
Medak Dist Rict, Andhra Padesh - 502291.
Our report of even date is to be read along with this letter:
1. Maintenance of Secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain responsible assurance about the correctness of the contents of secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices that we follow provide a responsible basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
4. Wherever required, we have obtained the Management Representation about the Compliance of laws, rules and regulations and happening of events etc.
5. The Compliance of the provision of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to verification of procedures on test basis.
6. The secretarial audit report is neither an assurance as to the future viability of the Company nor the efficacy or effectiveness with which the management has conducted the affairs of the Company.
Sd/-.
Ashwini Rajeshirke
Practising Company Secretary
ACS No.: 26223
C P No.: 9746
Place: Mumbai
Date: 03.09.2015
Avon Lifesciences Ltd
1716
22nd ANNUAL REPORT
I REGISTRATION & OTHER DETAILS:
II PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY
III PARTICULARS OF HOLDING , SUBSIDIARY & ASSOCIATE COMPANIES
All the business activities contributing 10% or more of the total turnover of the company shall be stated
Sl No Name & Address of the Company CIN/GLN HOLDING/SUBSIDIARY/ASSOCIATE
Total 14309100 63.60% 0.00% 11009100 48.93% 0.00% -23.06%
Shareholding Pattern of top ten Shareholders (other than Direcors, Promoters & Holders of GDRs & ADRs)(iv)
Shareholding of Directors & KMP(v)
Sl. No ParticularsShareholding at the end
of the year
Cumulative Shareholding during
the year
For Each of the Directors & KMPNo.of
shares
% of total shares of the
company
No of shares
% of total shares of
the company
1 At the beginning of the year 0 0 0 0
Date wise increase/decrease in Promoters Share holding during the year specifying the reasons for increase/decrease (e.g. allotment/transfer/bonus/sweat equity etc)
0 0 0 0
2 At the end of the year 0 0 0 0
Sl. No ParticularsShareholding at the
beginning of the yearShareholding at the end
of the year
For Each of the Top 10 ShareholdersNo.of
shares
% of total shares of the
company
No of shares
% of total shares of
the company
1 APAAR FINANCE AND INVESTMENT LTD 0 0.00% 720000 3.20%
2 BLUE PEACOCK SECURITIES PVT LTD 0 0.00% 654032 2.91%
8 GULSHAN INVESTMENT COMPANY LTD 0 0.00% 168705 0.75%
9 ANJU GUPTA 0 0.00% 160000 0.71%
10ANDHRA PRADESH INDUSTRIAL DEVELOPMENT CO
157500 0.70% 157500 0.70%
Avon Lifesciences Ltd
2120
22nd ANNUAL REPORT
INDEBTEDNESS(V)
REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL
(A) Remuneration to Managing Director, Whole time director and/or Manager:
(VI)
Sl.No Particulars of Remuneration Name of the MD/WTD/Manager Total Amount
1 Gross salary N.A. N.A. N.A.
(a) Salary as per provisions contained in section 17(1) of the Income Tax. 1961.
NIL NIL NIL NIL
(b) Value of perquisites u/s 17(2) of the Income tax Act, 1961
NIL NIL NIL NIL
(c ) Profits in lieu of salary under section 17(3) of the Income Tax Act, 1961
NIL NIL NIL NIL
2 Stock option NIL NIL NIL NIL
3 Sweat Equity NIL NIL NIL NIL
4 Commission NIL NIL NIL NIL
as % of profit NIL NIL NIL NIL
others (specify) NIL NIL NIL NIL
5 Others, please specify NIL NIL NIL NIL
Total (A) NIL NIL NIL NIL
Ceiling as per the Act
Indebtedness of the Company including interest outstanding/accrued but not due for payment
Particulars Secured Loans excluding deposits
Unsecured Loans
Deposits Total Indebtedness
Indebtness at the beginning of thefinancial year
i) Principal Amount 1,172,647,224 160,481,607 0 1,333,128,831
ii) Interest due but not paid 36,778,939 0 0 36,778,939
iii) Interest accrued but not due 0 0 0 0
Total (i+ii+iii) 1,209,426,163 160,481,607 0 1,369,907,770
Change in Indebtedness during thefinancial year
Additions 54,246,758 0 0 54,246,758
Reduction 0 0 0
Net Change 54,246,758
Indebtedness at the end of thefinancial year
i) Principal Amount 1,142,250,999 160,481,607 0 1,302,732,606
ii) Interest due but not paid 121421922 0 0 121,421,922
iii) Interest accrued but not due 0 0 0 0
Total (i+ii+iii) 1,263,672,921 160,481,607 0 1,424,154,528
(B) Remuneration to other directors:
(C) REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD
Sl.No Particulars of Remuneration Name of the Directors Total Amount
1 Independent Directors Dr. Sunil Pitroda
(a) Fee for attending board committee meetings 30,000 NIL
(b) Commission NIL NIL
(c ) Others, please specify NIL NIL
Total (1) NIL NIL
2 Other Non Executive Directors
(a) Fee for attending board committee meetings
NIL NIL
(b) Commission NIL NIL
(c ) Others, please specify. NIL NIL
Total (2)
Total (B)=(1+2) NIL NIL
Total Managerial Remuneration NIL NIL
Overall Cieling as per the Act. N.A N.A
Sl. No. Particulars of Remuneration Key Managerial Personnel
1 Gross Salary CEO
Company Secretary
Mr. Jignesh Patel
CFO Total
(a) Salary as per provisions contained in section 17(1) of the Income Tax Act, 1961. (Gross CTC)
NIL 600,000 NIL 600,000
(b) Value of perquisites u/s 17(2) of the Income Tax Act, 1961
NIL NIL NIL NIL
(c ) Profits in lieu of salary under section 17(3) of the Income Tax Act, 1961
NIL NIL NIL NIL
2 Stock Option NIL NIL NIL NIL
3 Sweat Equity NIL NIL NIL NIL
4 Commission as % of Profit NIL NIL NIL NIL
5 Others, NIL NIL NIL NIL
Total NIL 600000 NIL NIL
Avon Lifesciences Ltd
2322
22nd ANNUAL REPORT
Type Section of the Companies Act
Brief Description
Details of Penalty/Punishment/Compounding fees imposed
Authority (RD/NCLT/Court)
Appeall made if any (give details)
A. COMPANY
Penalty N.A N.A N.A N.A N.A
Punishment N.A N.A N.A N.A N.A
Compounding N.A N.A N.A N.A N.A
B. DIRECTORS
Penalty N.A N.A N.A N.A N.A
Punishment N.A N.A N.A N.A N.A
Compounding N.A N.A N.A N.A N.A
C. OTHER OFFICERS IN DEFAULT
Penalty N.A N.A N.A N.A N.A
Punishment N.A N.A N.A N.A N.A
Compounding N.A N.A N.A N.A N.A
PENALTIES/PUNISHMENT/COMPPOUNDING OF OFFENCES(vii) MANAGEMENT DISCUSSION AND ANALYSIS REPORT
The recent spurt in emerging markets has directly impacted the pharmaceutical industry. Rising affordability, enhanced life expectancy and improved standard of living are all providing impetus to the demand for pharmaceuticals. the result of new (and ongoing) research and development activities are yet to show the same flair as their predecessors, we can be assured that such loss of exclusivities certainly enables new players to enter into the market thereby increasing the potential for sales. with rise labor costs in China are set to change the API landscape. The API industry is expected to witness the rise of second wave emerging markets in countries such as Brazil, Mexico, South Korea and Taiwan. The Taiwanese API producers have gained recognition for high quality and international good manufacturing practices (GMP) compliance.
According to report of, "Global API Market Outlook 2018", in the wake of the above developments, the Global API industry is expected to grow at a CAGR of 9.4% from 2013-2018. The market has been divided into four major geographies which comprise Americas, Asia, Europe and the rest of the world. A list of top countries which will be responsible for the majority of API related activities are US, Italy, Japan, China, India and South Korea.
As a result of the more and more regulatory compliances requirements and escalating R&D costs, fiscal austerity measures introduced by governments across many developed countries in the past few years have presented tremendous challenges for both innovator and generic drug makers.
The Indian Pharma Market (“IPM”) is valued at Rs. 903 billion (IMS, MAT March 2015) and is expected to grow at a CAGR of eleven (11) per cent over the next four years. It continues to be a highly fragmented market with a large number of players spread across therapeutic segments.
Risks and Concerns
With a population exceeding 1.2 billion, India is a major market for healthcare companies. According to statistics from the Pharmaceutical Export Promotion Council (or Pharmexcil) on the India Brand Equity Foundation (or IBEF) website, the domestic pharmaceuticals sector in India is experiencing strong growth. This growth is mainly due to increasing penetration into the rural market, which is still largely untapped.
Although India exports pharmaceutical products to more than 200 countries, the US remains the major importer of pharmaceutical products from India—accounting for approximately one-fourth of India's exports in this sector. The Indian pharmaceutical industry, which was estimated to be worth $12 billion during 2013, is expected to grow to $100 billion over the next decade.
• Huge outsourcing opportunity in Indian APIs industry
• One of the few Indian players in a fast growing Veterinary segment
• Increased thrust on product partnerships by global pharma companies
• Competition from other Companies operating in similar segments
• Lack of proper Infrastructure facilities.
• Other key risks related to our business may include loss of key personnel, increased labour costs and uncertainties in terms of regulatory changes
• Unavailability of proper health insurance
Finance
Operational &Financial Performance
• Sales: During the year under review, owing to sluggish external factors and various issues at the customers end beyond the control of the Management. The Total income was down from Rs. 5707.04 Lacs to Rs. 2911.48 Lacs during the period of review.
Gross Margin (EBIDTA): During the year under review, the Gross margin (Loss) stood at Rs. 939.77 Lakhs as against Gross margin (Loss) of Rs. 427.05Lakhs.
PHARMACEUTICAL INDUSTRY OVERVIEW
INDIAN PHARMACEUTICAL MARKET
According to McKinsey report Indian Pharma 2020. The Indian Pharma industry is poised for expansion and is expected to grow to US$55 billion by 2020 High economic growth, rapid urbanisation resulting in lifestyle diseases, increased government spending on healthcare, improved healthcare facilities and healthcare insurance plans are some of the growth drivers for the pharma industry.
Some of the keys Opportunities available to the Company are as follows:
Some of the keys risks and concerns that are faced by the Company are as follows:
Avon Lifesciences Ltd
2524
22nd ANNUAL REPORT
Avon Lifesciences Ltd
2726
22nd ANNUAL REPORT
•Lakhs loss in the last financial year.
• Net-worth: The net-worth of the Company decreased to Rs. 1367.12Lakhs from Rs. 4457.02 Lakhs during the previous year. The decrease has been primarily on account of loss incurred by the company during the year under review.
Internal Control Systems
The Company has internal control systems in place commensurate with the size and industry it operates in. Its always our endeavor to strictly adheres to the laws, rules and statues of the land, and ensures compliance at all levels and across all divisions and departments. Any concerns raised are immediately address and corrected.
There is a proper definition of roles and responsibilities across the organization to ensure information flow and monitoring. The Audit Committee of the Company reviews the statutory audit reports, the quarterly and annual financial statements and discusses all significant audit observations and follow up actions arising from them.
Human Resource Development and Industrial Relations
Avon's HR function is dedicated to overall growth vision of the Company and continuously works on areas such as recruitment and selection policies, disciplinary procedures, reward/recognition policies, learning and development policies and all round employee development. Avon provides a safe and rewarding environment that attracts and retains a talented team and where employees are engaged in delivering exceptional results to the customers and investors.
Cautionary Statement
Statements in the Management Discussion and Analysis describing the Company's objectives, projections, estimate, expectations may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results could differ materially from those expressed or implied. Important factors that could make a difference to the Company's operations include, among others, economic conditions affecting demand/supply and price conditions in the domestic and overseas markets in which the Company operates, changes in the Government regulations, tax laws and other statutes and incidental factors.
Net Profit/(Loss) : During the year the Net Loss of the Company stood at Rs. 3,025.60 Lakhs as against 3,257.34 Report on Corporate Governance
1. COMPANY'S PHILOSOPHY ON CODE OF CORPORATE GOVERNANCE
Your Company adheres to best practices in Corporate Governance in its true spirit and benchmarks it with highest standards. Good Corporate Governance leads to long-term shareholder value and enhances interests of all stakeholders by creating wealth and shareholder value.
Avon's philosophy on Corporate Governance is cast strong emphasis on transparency, accountability, responsibility, fairness, integrity, consistent value systems and delegation across all facets of its operations leading to sharply focused and operationally efficient growth. The Company's beliefs on Corporate Governance are intended at supporting the management of the Company for competent conduct of its business and ensuring long-term value for shareholders, as well as customers, suppliers, employees and statutory authorities
The Board of Directors fully supports and endorses Corporate Governance practices as enunciated in Clause 49 of the Listing Agreement as applicable from time to time.
Code of Conduct:
The Board has laid down a Code of Conduct for all Board members and Senior Managerial personnel of the Company. The Code of Conduct is available on the web site of the Company at http://avonlifesciences.com
All the Board Members and Senior Managerial Personnel have affirmed compliance with the Code of Conduct and a declaration to that effect signed by the Chairman has been obtained.
Profile of members of the Board of Directors being appointed/re-appointed:
Details of Director seeking appointment/re-appointment at the forthcoming Annual General Meeting as required under clause 49 of the listing agreement is annexed to the Notice convening the Annual General Meeting which forms part of this Annual Report.
2. BOARD OF DIRECTORS:
The Board as on 31st March, 2015 consists of 4 directors, 3 Non-Executive Promoter Directors and 1 Independent Director.
Details of composition of the Board, category, attendance of Directors at the Board Meetings and last Annual General Meeting (AGM), number of other Directorships and Committee Memberships as on 31st March, 2015 are given below:
*Whole time Director w.e.f 5-8-2015
Number of Board Meetings:
During the year, Ten (10) Board Meeting were held and the details are given below:
SR. No
Name, Designation and DIN of Directors
Category No. of Board Meetings Attended
No. of Directorships held in other Companies(+)
Attendance at last AGM
No. of Committee positions held in other Companies.
Chairman of Committee
Member of Committee
1 Mr. Ajit Kamath Chairman/ (Promoter)
10 15 No 1 1
2 Mr. Manoj Jain* Non-Executive (Promoter)
10 5 Yes NIL NIL
3 Mr. Rajendra Kaimal
Non-Executive (Promoter)
10 14 Yes NIL NIL
4 Dr. Sunil Pitroda Non-Executive (Independent)
5 NIL No NIL NIL
Avon Lifesciences Ltd
2928
22nd ANNUAL REPORT
3. COMMITTEES OF THE BOARD:
As per the requirement of the Companies Act, 2013 read with Rules and amended clause 49 of the Listing Agreement. The Board of Directors has constituted four Committees i.e. Audit Committee, Stake Holder Relationship Committee, Remuneration and Nomination Committee and Corporate Social Responsibility Committee. The roles and responsibilities assigned to these Committees are covered under the terms of reference approved by the Board and are subject to review by the Board from time to time. The minutes of the meetings of Audit Committee, Stake Holder Relationship Committee, Remuneration and Nomination Committee are placed before the Board for their information and noting. The details as to the composition, terms of reference, number of meetings and related attendance etc. of these Committees are given below:
a) Audit Committee
Composition, meetings and the attendance during the year
Four (4) meetings of the Audit Committee were held on 30th May, 2014, 14th August, 2014, 08th November, 2014 and 04th February, 2015. The details of composition of the Committee and their attendance at the meetings are given below:
As on March 31, 2015 in the absence of Non-Executive Independent Directors on the Board of the Company, the Composition of the committee was not in compliance with Clause 49 of the Listing Agreement and Section 177 of the Companies Act, 2013
Members of the Audit Committee have requisite financial and Management expertise.
* Appointed as a member w.e.f. 05th December, 2014.
The Company Secretary acts as Secretary of the Committee.
Terms of Reference
The terms of reference to this committee, interalia covers all the matters specified under Clause 49 of the Listing Agreement with the stock exchanges as well as in Section 177 of the Companies Act, 2013, besides other terms as may be referred by the Board of Directors, from time to time. The Audit Committee has also powers inter alia to investigate any activity within its terms of reference and the Committee lays emphasis on adequate disclosures and compliance with all relevant statues.
b) Nomination & Remuneration Committee:
Composition, meetings and the attendance during the year
During the financial year 2014-15, Two (2) meeting of the Remuneration and Nomination Committee were held on 20th November, 2014 and 05th December, 2014. The details of composition of the Committee and their attendance at the meeting are given below:
As on March 31, 2015 in the absence of Non-Executive Independent Directors on the Board of the Company, the Composition of the committee is not in compliance with Clause 49 of the Listing Agreement and section 178 of the Companies Act, 2013.
Sr No. Date Board Strength No. of Directors Present
1 30-05-2014 3 3
2 14-08-2014 3 3
3 03-09-2014 3 3
4 08-11-2014 3 3
5 20-11-2014 3 3
6 05-12-2014 3 3
7 12-01-2015 4 3
8 04-02-2015 4 4
9 13-02-2015 4 4
10 23-03-2015 4 4
* Appointed as a member w.e.f. 05th December, 2014.
The Company Secretary acts as Secretary of the Committee.
Terms of Reference
The Committee was constituted to:
• To guide the Board in relation to appointment and removal of Directros, KMP and senior Management.
• To review and recommend managerial remuneration, based on their performance and defined assessment criteria.
• To evaluate the performance of the Board members and provide necessary report to the Board for further evaluation of the Board.
• To retain, motivate and promote talent and to ensure long-term sustainability of talented managerial persons and create competitive advantage.
• To devise policy on Board diversity
• To develop succession plan for the Board and review the plan regularly.
Policy for Remuneration to Directors/Key Managerial Personnel's:
During the financial year under review Directors are not paid any salary.
• Remuneration to Managing Director/Wholetime Directors
a) The Remuneration/Commission etc. to be paid to Managing Director/Wholetime Directors, etc. shall be governed as per provisions of the Companies Act, 2013 and rules made there under or any other enactment for the time being in force and the approvals obtained from the Members of the Company.
b) The Remuneration and Nomination Committee shall make such recommendations to the Board of Directors, as it may consider appropriate with regard to remuneration to Managing Director/Wholetime Directors
• Remuneration to Non-Executive/Independent Directors:
a) The Non-Executive/Independent Directors may receive sitting fees and such other remuneration as permissible under the provisions of Companies Act, 2013. The amount of sitting fees shall be such as may be recommended by the Remuneration and Nomination Committee and approved by the Board of Directors.
b) All the remuneration of the Non-Executive/ Independent Directors (excluding remuneration for attending meetings as prescribed under Section 197(5) of the Companies Act, 2013) shall be subject to ceiling/limits as provided under Companies Act, 2013 and rules made there under or any other enactment for the time being in force. The amount of such remuneration shall be such as may be recommended by the Remuneration and Nomination Committee and approved by the Board of Directors or shareholders, as the case may be.
c) An Independent Director shall not be eligible to get Stock Options and also shall not be eligible to participate in any share based payment schemes of the Company.
d) Any remuneration paid to Non-Executive/ Independent Directors for services rendered which are of professional nature shall not be considered as part of the remuneration for the purposes of above clause if the following conditions are satisfied:
i. The Services are rendered by such Director in his capacity as the professional; and
ii. In the opinion of the Committee, the Director possesses the requisite qualification for the practice of that profession.
However, appropriate sittings fees were paid to Independent Director of the Company during the year under review.
Name Designation Category No. of Meetings Attended
Mr. Ajit Kamath Chairman Non-Executive (Promoter) 4
Mr. Manoj Jain Member Non-Executive (Promoter) 4
Mr. Rajendra Kaimal Member Non-Executive (Promoter) 4
Dr. Sunil Pitroda* Member Non-Executive (Independent) 1
Name Designation Category No. of Meetings Attended
Mr. Rajendra Kaimal Chairman Non-Executive (Promoter) 2
Mr. Ajit Kamath Member Non-Executive (Promoter) 2
Mr. Manoj Jain Member Non-Executive (Promoter) 2
Dr. Sunil Pitroda* Member Non-Executive (Independent) NIL
Avon Lifesciences Ltd
3130
22nd ANNUAL REPORT
•
a) The remuneration to Key Managerial Personnel shall consist of fixed pay only, in compliance with the provisions of the Companies Act, 2013 and in accordance with the Company's Policy.
b) The Fixed pay shall include monthly remuneration, employer's contribution to Provident Fund, contribution to pension fund, pension schemes, etc. as decided from time to time in accordance with the Company's Policy.
The details of remuneration are given in form MGT-9 which forms part of the Directors Report.
c) Stake Holder Relationship Committee:
Composition, meetings and the attendance during the year
Four (4) meetings of the Audit Committee were held on 30th May, 2014, 14th August, 2014, 08th November, 2014 and, 04th February, 2015. The details of composition of the Committee and their attendance at the meetings are given below:
As on March 31, 2015 in the absence of Non-Executive Independent Directors on the Board of the Company, the Composition of the committee is not in compliance with Clause 49 of the Listing Agreement and Section 178 of the Companies Act, 2013
* Appointed as a member w.e.f. 05th December, 2014.
The Company Secretary is designated as the compliance officer by the Company and acts as Secretary of the Committee.
Company received 11 complaints during the year and all of them have been redressed/answered to the satisfaction of the Shareholders. No investor grievance remained unattended/pending for more than 30 days.
d) Corporate Social Responsibility Committee (CSR):
During the financial year 2014-15, no meeting of the committee was held, since the occasion for it did not arise.
The Composition of the Committee is given below:
* Appointed as a member w.e.f. 05th December, 2014.
The Company Secretary acts as Secretary of the Committee.
Terms of reference
Decide, Formulate and recommend the CSR policy to the board which shall indicate the activities to be undertaken by the Company, recommend the amount of expenditure to be incurred on the activity and monitor the CSR policy of the Company from time to time.
e) INDEPENDENT DIRECTORS MEETING:
As on the 31.03.2015 Company had only one Independent director on the Board of the Company.
4. GENERAL BODY MEETINGS:
Details of the Annual General Meetings held during the preceding 3 years and Special Resolutions passed thereat are given below:
Remuneration to Key Managerial Personnel:
b) Postal Ballot:
During the year, the Company had sought approval from the shareholders; The Company had also provided e-voting facility for the postal ballot. The Company had appointed Ms. Ashwini Rajshekre, Practicing Company Secretary to act as Scrutinizer for the entire Postal Ballot process. The result of the same was as under:
5. DISCLOSURES:
a) There were no transactions of material nature with its related parties that may have the potential conflict with the interest of the Company at large. Transactions with related parties are disclosed in Note to the Financial Statements.
b) There were no instances of non-compliance nor have any penalties/strictures imposed by Stock Exchanges or SEBI or any other statutory authority on any matters related to capital market, during last 3 financial years.
c) The Board of Directors of the Company has adopted and put in place a Whistle Blower Policy and no personnel have been denied access to the audit committee.
d) Compliance with Accounting Standards:
In preparation of the Financial Statements, the Company has followed the Accounting Standards applicable to the Company.
Name Designation Category No. of Meetings Attended
Mr. Rajendra Kaimal Chairman Non-Executive (Promoter) 4
Mr. Ajit Kamath Member Non-Executive (Promoter) 4
Mr. Manoj Jain Member Non-Executive (Promoter) 4
Dr. Sunil Pitroda* Member Non-Executive (Independent) 1
Name Designation Category No. of Meetings Attended
Mr. Rajendra Kaimal Chairman Non-Executive (Promoter) N.A
Mr. Ajit Kamath Member Non-Executive (Promoter) N.A
Mr. Manoj Jain Member Non-Executive (Promoter) N.A
Dr. Sunil Pitroda* Member Non-Executive (Independent) N.A
Year Day, Date and Time
of the Meeting
Venue Details of Special Resolutions passed
2014 Tuesday, 30 th December,
2014, 10.00 a.m.
Hotel Daspalla,Road no. 37,Jubilee Hills,
Hyderabad - 500033
i. Authorisation to borrow under section 180 (1)
(c) of the Companies Act, 2013
ii. Authorisation to mortgage the assets of the
Company under Section 180 (1) (a) of the
Companies Act, 2013
2013 Saturday, 21st September,
2013, 10.00 a.m.
No Special Resolution was passed.
2012 Friday, 28 th September,
2012, 10.00 a.m.
No Special Resolution was passed.
Hotel Daspalla,Road no. 37,Jubilee Hills,
Hyderabad - 500033
Hotel Daspalla,Road no. 37,Jubilee Hills,
Hyderabad - 500033
Sr No. Particulars Resolution No. 1
Resolution No. 2
Resolution No. 3
Resolution No. 4
Resolution No. 5
Resolution No. 6
1 Type of resolution
Ordinary Resolution
Ordinary Resolution
Special Resolution
Special Resolution
Special Resolution
Special Resolution
2 Subject matter of resolution
Increase in the Authorized Share Capital
Alteration of the Capital Clause of the MOA
Offer, Issue & Allot Warrants on Preferential Basis
Change in the name of the Company
Adoption of new Articles of Association
Shifting of Registered office of the Company to solapur, Maharashtra.
The Chairman and Non - Executive Director of the Company have certified to the Board with regard to the compliance made by them in terms of Clause 49 (IX) of the Listing Agreement and the certificate forms part of Annual Report.
f) Internal control system and their adequacy:
The Company has adequate internal control procedures commensurate with its size and nature of business. The Audit Committee of the Board of Directors periodically reviews the audit plans, internal audit reports and adequacy of internal controls and risk management.
6. MEANS OF COMMUNICATION
Financial Results: The quarterly, half-yearly and annual results of the Company are published in widely circulated newspapers viz. The Financial Express (a national daily) and Andhra Prabha (a regional daily). These are also submitted to the Stock Exchanges on which the company's shares are listed in accordance with the Listing Agreement.
Annual Report: Annual Report of the Company containing, inter-alia, Audited Financial Statements, Directors' Report, Report on Corporate Governance, Auditors Report and other important information is circulated to the members and others entitled thereto for each financial year. The Management Discussion and Analysis Report forms part of the Annual Report.
7. GENERAL SHAREHOLDERS' INFORMATION
1. Date, Time and Venue of AGM: Wednesday, 30th September, 2015 at 10 a.m.
(ii) Non-Operational: Survey No.18, Yawapur Village, Sadasivpeth Mandal, Medak Dist, Telangana.
15. Address for Correspondence Shareholder correspondence should be addressed to the Company's R & T Agent or to the secretarial department of the Company.
16. Dematerialisation of shares And liquidity: Trading in equity shares of the company became mandatory from July, 2001. As on 31st March, 2015, 2,23,56,784 Equity shares equivalent to 99.36 % of the paid up share capital of the company are in dematerialized form. The company's shares are currently traded in B group on the BSE, Mumbai.
17. Outstanding GDR/ADR/Warrants or any As on 31.03.2015, the Company has not issued and alloted any of these types of securities, convertible instruments, conversion date and likely impact of Equity.
However on 12.08.2015 the Company has issued 1,05,00,000 warrants convertible in to Equity Shares to Non-Promoters on Preferential basis.
18. Share Transfer System S h a r e s s e n t f o r p h y s i c a l t r a n s f e r o r dematerialization requests are generally registered and returned within a period of 15 days from the date of receipt of completed and validly executed documents.
Bad deliveries are promptly returned to Depository Part icipants (DPs) under advice to the shareholders.
19. Stock Market data relating to shares listed
Month Bombay Stock Exchange (Amt. In Rs)
High Price Low Price Apr-14 11.50 9.10
May-14 15.03 9.00
Jun-14 13.05 9.80
Jul-14 13.65 10.26
Aug-14 12.95 9.85
Sep-14 15.00 9.81
Oct-14 13.75 11.82
Nov-14 13.95 10.42
Dec-14 12.00 10.01
Jan-15 20.88 10.52
Feb-15 26.70 21.25
Mar-15 30.25 24.75
Avon Lifesciences Ltd
3534
22nd ANNUAL REPORT
20. Distribution of Shareholding as on 31st March, 2015.
Categories Number % of Holders No. of shares held % of shares
Resident Individuals 5023 95.42 7556362 33.58
NRI's, FII's, OCB's 37 0.70 93011 0.41
Bodies Corporate 184 3.50 3530563 15.69
Promoters, Directors,Associates
1 0.02 11009100 48.93
Mutual funds, Banks, FI's 2 0.04 157600 0.70
Others (Clearing Members) 17 0.32 153364 0.68
Total 5264 100.00 22500000 100.00
Avon Share Price vs. BSE Sensex
Avon BSE Sensex
30
25
20
15
10
5
0
35000
30000
25000
20000
15000
10000
5000
0Apr
2014May2014
Jun2014
Jul2014
Aug2014
Sep2014
Apr2014
Nov2014
Dec2014
Jan2015
Feb2015
Mar2015
CERTIFICATE OF COMPLIANCE WITH THE CODE OF CONDUCT
To
The Shareholders,
I hereby declare that all the Board Members and the senior management personnels have affirmed compliance with the code of conduct adopted by the company and have submitted declarations in this behalf for the year ended 31st March, 2015.
Place : Mumbai Ajit Kamath
Date : 29.05.2015 Chairman
CERTIFICATE FROM CHAIRMAN
I, Ajit Kamath, Director of the Company, to the best of my knowledge and belief, certify that:
a. I have reviewed the financial statements and the cash flow statement for the year under review and certify that:
i. these statements do not contain any materially untrue statement or omit any material facts or contain statements that might be misleading.
ii. these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
b. To the best of my knowledge and belief, no transactions entered into by the company during the year are fradulent, illegal or violate of the company's code of conduct.
c. I am responsible for establishing and maintaining internal controls for financing reporting and have evaluated the effectiveness and disclosed to the auditors and audit
committee, the deficiencies in the design and operation of such internel controls and the steps taken to rectify these deficiencies.
d. I have indicated to the auditors and audit committee that -
i. there are no significant changes in internal control over financial reporting during the year.
ii. there are no significant changes in accounting policies during the year and the same have been disclosed in the notes to the financial statements.
iii there are no frauds of which i was aware, that involves management or other employees who have a significant role in the company's internel control system.
Place : Mumbai Ajit Kamath
Date : 29.05.2015 Chairman
Bodies Corporate15.69%
NRIs. FIIs, OCBs0.41%
Resident Individuals33.58%
Others0.68%
Mutual Funds,Banks, Flis
0.70%
Promoters,Directors, Associates
48.93%
Avon Lifesciences Ltd
3736
22nd ANNUAL REPORT
AUDITORS' CERTIFICATE ON CORPORATE GOVERNANCE
To
The Members of
AVON ORGANICS LIMITED
We have examined the compliance conditions of Corporate Governance by AVON ORGANICS LIMITED for the year ended 31st March, 2015 as stipulated in Clause 49 of the Listing Agreement of the said Company with Stock Exchanges in India
The compliance of Corporate Governance is the responsibility of the management. Our examination was limited to the procedures and implementation thereof adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statement of the Company.
In our opinion and the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the Listing Agreement mentioned above.
We state that in respect of investor grievances received during the year ended 31st March, 2015 no investor grievances are pending for a period more than one month against the Company as per the records maintained by the Company and presented to the Investor Grievance Committee.
We further state that such compliance is neither an assurance as to future viability of the Company nor the efficiency with which the management has conducted the affairs of the Company.
For Mukesh Mehta & Associates
Chartered Accountants.
Sd/-
Mukesh Mehta
Proprietor
Membership No. 100407
FRN:116309W
Place: Mumbai
Date: 29.05.2015
AUDITOR’S REPORT
To
The Members of Avon Organics Limited
Report on the Financial Statements
We have audited the accompanying financial statements of Avon Organics Limited, which comprise the balance sheet as at 31 March 2015, the statement of profit and loss and the cash flow statement for the year then ended, and a summary of significant accounting policies and other explanatory information.
Management's Responsibility for the Financial Statements
The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 with respect to the preparation and presentation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
Auditor's Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.
We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.
Opinion
In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India.
stI. In so far as it relates to the Balance Sheet, of the statement of affairs of the company as at 31 March 2015.
ii. In so far as it relates to the Profit & Loss Account , the Loss of the company for the year ended on that date: and
iii. In so far as it relates to the Cash Flow Statement , of the Cash flow of the Company for the year ended on that date: and
Report on Other Legal and Regulatory Requirements
1. As required by the Companies (Auditor's Report) Order, 2015 issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure a statement on the matters specified in the paragraph 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143 (3) of the Act, we report that:
a. we have sought and obtained all the information and explanations which to the best of our knowledge and
Avon Lifesciences Ltd
3938
22nd ANNUAL REPORT
belief were necessary for the purposes of our audit.
b. in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
c. the balance sheet, the statement of profit and loss and the cash flow statement dealt with by this Report are in agreement with the books of account;
d. in our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
e. on the basis of the written representations received from the directors as on 31 March 2015 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2015 from being appointed as a director in terms of Section 164 (2) of the Act; and
f. with respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us :I. the Company has disclosed the impact of pending litigations on its financial position in its financial
statements – Refer Note 11 to the Significant Accounting Policy;ii. the provisions as required under the applicable law or accounting standards for material foreseeable
losses if any on the long term contracts including derivative contracts are not applicable to the company.iii. There has been no such requirement for transferring amounts, required to be transferred the Investor
Education and Protection Fund transfer by the company.
For Mukesh Mehta & Associates
Chartered Accountants.
Sd/-
Mukesh Mehta
Proprietor
Membership No. 100407
FRN:116309W
Place: Mumbai
Date: 29.05.2015
Annexure to the Auditors' Report
The Annexure referred to in our Independent Auditors' Report to the members of the Company on the financial statements for the year ended 31 March 2015, we report that:
(i) (a) The Company has maintained proper records showing full particulars, including details and situation of fixed assets.
(b) The Company has a regular programme of physical verification of its fixed assets by which fixed assets are verified in a phased manner at regular intervals. In accordance with this programme, certain fixed assets were verified during the year and no material discrepancies were noticed on such verification. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets.
(c) During the year, the company has not disposed of any substantial part of its fixed assets and going concern status of the company not affected.
(ii) In respect of its inventories:
(a) The inventories has been physically verified during the year by the management at reasonable intervals. In our opinion the frequency of verification is reasonable.
(b) In our opinion and according to the information and explanation given to us, the procedure of physical verification of inventories followed by the management is reasonable and adequate in relation to the size of the company and nature of its business.
(c) On the basis of our examination of records of inventory, we are of the opinion that the company is maintaining proper records of inventory. The discrepancies noticed on physical verification between the physical stocks and book stocks were not material.
(iii) (a) The Company has not granted any loans to the bodies corporate covered in the register under section 189 of the Companies Act, 2013 ('the Act').
(b) The company has given interest free loan to Associate Concern of the company. In the said loans, the maximum amount outstanding at any time during the year was Rs. 51,015 and the year end balance was Rs. 51,015.
(c) The company has taken unsecured interest free loans from the bodies corporate covered in the register maintained under section 189 of the Act and the amount outstanding at the end of the year is Rs. 3171.40 lacs (Previous year Rs. 3171.40 lacs).
(iv) In our opinion and according to the information and explanations given to us, there is an adequate internal control system commensurate with the size of the Company and the nature of its business with regard to purchase of inventory, fixed assets and sale of goods. During the course of our audit, no major weakness has been noticed in the internal control system and there is no continuing failure to correct any major weakness in internal control.
(v) The Company has not accepted any deposits from the public.
(vi) The Central Government has prescribed the maintenance of cost records under section 148(1) of the Act, to the company and such accounts and records have been made and maintained by the company.
(vii) According to the records of the company, the company is not regular in depositing the undisputed statutory dues including provident fund, Employees' State Insurance, Profession Tax, Income Tax, TDS, Sales tax, Excise Duty, Service Tax, Cess and any other statutory dues with the appropriate govt and semi govt authorities. There are arrears of outstanding such undisputed statutory dues at the last day of the financial year concerned for a period of more than six months from the date they became payable.
ESIC 31,418
Provident Fund 5,374,975
Professional Tax 804,850
TDS 2,368,180
Sales Tax 777,027
Service Tax 2,224,102
Excise Duty 1,497,195
Income Tax 32754530
Avon Lifesciences Ltd
40
(viii) The company has incurred cash losses of Rs. 2501.64 lacs (previous year Rs. 2241.03 lacs) and accumulated losses of Rs. 5167.09 (previous year Rs. 2141.49 lacs) in profit and loss accounts. The company has eroded more than fifty percent of its entire paid up share capital by way of debit balance in profit and loss account.
(ix) Based on our audit procedures and on the information and explanations given by the management, we are of the opinion that the company has delay /defaulted in repayment of dues along with the interest thereon with the banks as at the end of the financial year.
(x) According to the records of the company and information and explanations given to us, the company has not given any guarantee for loans taken by others from banks or financial institutions.
(xi) According to the records of the company and explanations given to us, during the year the company has availed the term loans from banks/ financial institution and has been applied for the purpose for which they have been obtained.
(xii) According to the information and explanations given to us, no material fraud on or by the company has been noticed or reported during the course of our audit.
For Mukesh Mehta & Associates
Chartered Accountants.
Sd/-
Mukesh Mehta
Proprietor
Membership No. 100407
FRN:116309W
Place: Mumbai
Date: 29.05.2015
41
22nd ANNUAL REPORT
BALANCE SHEET AS AT 31.03.2015
Note
EQUITY AND LIABILITIESShareholder's FundsShare Capital 1 225,000,000
225,000,000
Reserves and Surplus 2 (88,287,717)
136,712,283
220,702,103
445,702,103
Non Current LiabilitiesLong Term Borrowing 3 393,934,323
442,724,340
Long Term Liability 4 317,140,209
317,140,209
Deferred tax liabilities (Net) 5 29,900,649
740,975,181
29,900,649
789,765,198
Current Liabilities Short Term borrowings 6 880,716,601 848,805,636Trade payables 7 514,762,945
525,833,598
Other current liabilities 8 221,424,245
144,971,196
Short term provisions 9 23,757,228
1,640,661,019
34,950,266
1,554,560,696
TOTAL 2,518,348,483
2,790,027,997
ASSETS
Non Current AssetsFixed AssetsTangible Assets 10 951,003,671
1,035,206,785
Intangible Assets -
-
Capital Work in Progress 22,506,617
22,506,617
Intangible assets under development -
973,510,288
-
1,057,713,402
Non Current Investment 11 121,930,256
121,930,256
Long Term Loans and Advances 12 51,015
51,015
CURRENT ASSETS
Inventories 13 699,675,180
760,112,648
Trade Receivables 14 561,646,543
653,119,354
Cash & Cash equivalents 15 2,417,655
14,195,284
Short terms loans and advances 16 19,107,570
45,361,880
Other Current Assets 17 140,009,975
1,422,856,924
137,544,158
1,610,333,324
TOTAL 2,518,348,483
2,790,027,997
Significant accounting policies and Notes on Financial statements 1 to 25
As at 31.03.2014 (Rs.)As at 31.03.2015 (Rs.)
Notes referred to above and thereto form an integral part of the Balance Sheet
As per our report of even date For and on behalf of the Board of Directorsfor Mukesh Mehta & Associates.Chartered Accountants
Deferred Sales Tax Loan from State Govts. 66,524,253 93,957,354 45,618,395 114,863,212
149,503,604 393,934,323 78,377,794 442,724,340
Arch Pharmalabs Limited
(13.48) (14.48)
As at 31.03.2015 (Rs.) As at 31.03.2014 (Rs.)
Avon Lifesciences Ltd
4544
22nd ANNUAL REPORT
3.1
3.2 Term Loan
The term loans from banks of Rs.3345.03 lacs (previous year Rs. 3089.72 lacs) are secured by way of first pari passu charge on fixed assets, second pari pasu charge on current assets, personal /corporate guarantees of promotor directors/ company.
The term loans from bank of Rs.484.54 lacs (previous year Rs. 516.49 lacs) are secured by way of first pari passu charge on current assets, second pari pasu charge on fixed assets, personal /corporate guarantees of promotor directors/ company.
3.3 Deferred Sales Tax Loan
The Company has been availing interest free Sales Tax deferment loan from States Government Authorities and the balance outstanding as on 31 st March, 2015 was Rs.1604.82 lacs (Previous year Rs. 1.604.82 lacs)
6.1 Working Capital
The working capital loans from the banks Rs. 8807.17 lacs (previous year Rs. 8488.06 lacs) are secured by first pari pasu charge on the current assets, second pari pasu charge on fixed assets and personal guarantee of promotor directors/company.
7.1 In the absence of necessary information with the company relating to information to the registration status of suppliers under the Micro, Small and Medium Enterprises Development Act, 2006, the information required under the said Act could not be complied and disclosed. The company has not received information from vendors regarding their status under the Micro, Small and Medium Enterprises.
Legal and Professional Charges 2,957,700 2,406,054
Rent, Rates & Taxes 123,045 1,092,370
Travelling & Conveyance 1,621,616 2,159,897
Printing & Stationery 154,775 412,266
Postage,Telegrams & Telephones 269,624 601,154
Auditors' Fees 150,000 150,000
General Expenses 23,751,899 9,950,483
29,485,101 17,771,399
Total 38,446,785 48,921,079
24.1 VALUE OF STORES, CHEMICAL AND PACKING MATERIAL CONSUMED
Particulars
Amount % of Consumption Amount % of Consumption
Imported - - - -
Indigenous 1,410,517 100.00% 4,679,335 100.00%
1,410,517 100.00% 4,679,335 100.00%
Year ended 31.03.2014Year ended 31.03.2015
SCHEDULE -25 - NOTES TO ACCOUNTSSignificant Accounting Policies & Notes to Accounts
I. Basis of Preparation of Financial Statements:
a) These financial statements are prepared in accordance with Indian Generally Accepted Accounting Principles (GAAP) under the historical cost convention on the accrual basis except for certain financial instruments which are measured at fair values. GAAP comprises mandatory accounting standards as prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified) and guidelines issued by the Securities and Exchange Board of India (SEBI). Accounting policies have been consistently applied except where a newly-issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.
b) The Company follows mercantile system of accounting and recognizes all significant items of income and expenditure on accrual basis.
c) All income & expenditure having material bearing on the financial statements are recognised on an accrual basis.
d) Use of Estimates: The preparation of financial statements in confirmity with generally accepted accounting principles requires management to make assumptions and estimates which it believes are reasonable under the circumstances that affect the reported amounts of assets, liabilities and contingent liabilities on the date of financial statements and the reported amounts of revenue and expenses during the year. Actual results could differ from those estimates. Difference between the actual results and estimates are recognised in the year in which the results are known/materialized.
II. Statement of Significant Accounting Policies:
A. Fixed Assets
All fixed assets are stated at Historical Cost less Depreciation except in the case of Land and Site Development whereas it is stated at Cost Plus Development expenditure. The expenses incurred in setting up the project are capitalised and apportioned to the assets procured for that project in proportion to the value of each of the asset.
B. Depreciation
The depreciation on fixed assets has been provided on Written Down Value method for Fixed Assets in Diketene Division and common assets at Corporate Office and on Straight Line Method for Assets in Bio-Tech Division over the useful life of assets as prescribed under Part C of Schedule II of the Companies Act, 2013 .Depreciation is not provided on Land. Depreciation on Assets acquired for the project are provided on Commercialisation and depreciation on other assets if put into use is provided accordingly. The management estimates the usefull lives for the Fixed Asset as follows:
C. Employees' Benefits
Contribution to defined schemes such as Provident Fund , ESI are charged as incurred on accrual basis.
D. Foreign Currency Transactions:
a. Transactions denominated in foreign currencies are recorded at spot rates / average rates.
b. Monetary items denominated in foreign currencies at the year end are restated at year end rates.
c. Non monetary foreign currency items are carried at cost.
d. In respect of branches, which are integral foreign operations, all transactions are translated at rates prevailing on the date of transaction or that approximates the actual rate on the date of transaction. Branch monetary assets and liabilities are restated at the year end rates.
e. Any income or expense on account of exchange difference either on settlement or on translation is
recognised in the Statement of Profit and Loss except in case of long term liabilities, where they relate to
acquisition of fixed assets, in which case they are adjusted to the carrying cost of such assets as applicable in AS 11
E. Inventories:
As per AS - 2 Inventories are valued as under:
a. Raw Materials, Stores, Consumables, Packing materials and other materials: at cost on Moving average basis
b. Work in process is carried at cost of input RM and estimated cost of manufacturing upto the stage of completion.
c. Finished Goods: At realizable value or cost whichever is lower.
F. Excise Duty, Service Tax and Education Cess
Excise Duty is accounted on the basis of payments made in respect of goods cleared. Cenvat , Service Tax and Education Cess on capital goods, raw materials and services as the case may be are accounted on receipt / completion of contracts, job works etc.
G. Revenue Recognition:
As per AS- 9 Revenue in respect of sales is recognised as and when goods are supplied and in respect of insurance claims, interest etc., is recognised when it is reasonably certain that the ultimate collection will be made.
H. R & D Expenditure:
Expenditure for capital items are debited to respective Fixed Assets and depreciation at applicable rates. Revenue expenditure is charged to Profit & Loss Account.
I. Deferred tax:
Deferred tax is accounted for by computing the tax effect of timing differences, which arise during the year and reversed in subsequent periods. Deferred Tax assets on accumulated losses and unabsored depreciation are recognised only to the extent there is certainity of realisation of such asset in future.
J. Earnings Per Share :
The basic and diluted Earnings Per Share is calculated by dividing the profit/(loss) after tax by the weighted average number of equity shares outstanding.
K. Impairment of Assets :
At each Balance Sheet date, the carrying values of the assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where there is an indication that there is a likely impairment loss for a group of assets, the company estimates the recoverable amount of the group of assets as a whole, to determine the value of impairment.
L. Investments:
Investments are stated at cost.
M. Borrowing Cost:
Borrowing Costs attributable to acquisition, construction or production of qualifying assets are capitalised as part of the cost of that asset, till the period in which the asset is ready for use. Other borrowing costs are recognised as an expense in the period in which these are incurred.
N. Provisions and Contingent Assets :
Provisions are recognised only when there is a present obligation as a result of past events and when a reliable estimate of the amount of the obligation can be made. Contingent liability is disclosed for i) possible obligations, which will be confirmed only by future events not wholly within the control of the company or ii) present obligation arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made. Contingent assests are not recognised in the financial statements since this may result in the recognition of income that may never be realised.
O. Cash and Cash Equivalents
Cash and cash equivalents comprise cash and cash on deposit with banks.
P. Cash Flow Statement
Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.
1 Contingent Liabilities not provided for : 2014-15 2013-14(in Rs.) (in Rs.)
a. Letters of Credit - - b. Bank Guarantees 2,500,000 3,500,000 c. Others 2,938,000 2,938,000
A. Value of ImportsRaw Materials 116,807,040 91,377,576
B. Value of Exports - Direct 183,199,978 19,879,340 C. Expenditure in Foreign Currency (Rs. )
Other Services - 7,875,560
4 The provision for taxation as well as MAT u/s 115JB is not made during the year due to current year loss.5 The Company is engaged solely in the business of 'Pharmaceuticals'. The entire operations are governed by the
same set of risks and returns and hence the same has been considered as representing a single segment. This treatment is in accordance with the guiding principles enunciated in the Accounting Standard 17 on 'Segment Reporting' as notified under the Companies Act, 2013. However the geographical break up of sales is as under:
6 Pursuant to AS-18 the names, relationships and particulars of transactions with related parties during the year are as under:
A) List of Related parties Sl No Particualrs Relationship1 Mr. Ajit Kamath Key Management Person2 Mr. Manoj Jain Key Management Person3 Mr. Rajendra Kaimal Key Management Person4 Mr. Jignesh Patel Key Management Person5 Arch Pharmalabs Ltd Associate Concern6 Regal Pharma Pte. Ltd. Associate Concern
B) The following transactions were carried with the related parties in the ordinary course of business during the year
Balances as on 31st March 2015Arch Pharmalabs Ltd Long Term Liability 317,140,209 317,140,209Regal Pharma Pte. Ltd Loans & Advances 51,015 51,015Regal Pharma Pte. Ltd Investment 121,930,256 121,930,256
7 The disclosure as per Accounting Standard (AS) 15 (Revised) "Employee Benefits" as notified by company (Accounting Standard) Rules, 2006 are as under:
Defined Contribution Plan Contribution to Defined Contribution Plan, recognised as expense for the year are as under:
As on 31.03.2014
3,907,883
Defined Contribution Plan
Employers Contribution to Provident Fund
As on 31.03.2015
1,120,203
Avon Lifesciences Ltd
5352
22nd ANNUAL REPORT
As per our report of even date For and on behalf of the Board
for Mukesh Mehta & Associates
Chartered Accountants
Mukesh Mehta Ajit Kamath Manoj Jain
Proprietor Chairman Director
Mem. No. 100407
FRN: 116309W
Place: Mumbai Rajendra Kaimal Jignesh Patel
Date: 29.05.2015 Director Company Secretary
Gratuity paid by the company is a defined benefit plan. The present value of obligation is determined based on actuarial valuation using the projected unit credit method, which recognizes each period of service as giving rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation.
8 The disclosure as per Accounting Standard (AS) 22 "Taxes on Income" as notified by Companies(Accounting Standard) Rules,2006 are as under.
9 The disclosure as per Accounting Standard (AS) 20 "Earnings per Share" as notified by Companies(Accounting Standard) Rules,2006 are as under:
Particulars 2014-15 2013-14In Rs. In Rs.
Net profit after tax (302,559,516) (325,734,118)Net Profit attributable to Equity shareholders (302,559,516) (325,734,118)Weighted Average number of equity shares outstanding during the year 22,500,000 22,500,000 Basic and Diluted Earnings per share (13.48) (14.48)Face Value per equity share 10.00 10.00
10 FINANCIAL AND DERIVATIVE INSTRUMENTS
Foreign currency exposure that are not hedged as on 31st March,2015 on account of:
11 The company has entered into the settlement agreement on April' 2015 with the workers employed in Sadashivpet Plant and the company has agreed to pay Rs. 282 lacs in full & final settlement of workers and the company will pay the amount in due course.
12 Exceptional Items and Changes in Accounting Policies Rs 253.76 Lakhs is towards reversal of certain employee related accruals made in earlier period.
13 Other Notes(a) Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current
year's classification / disclosure.(b) In the opinion of the Board of Directors, other current assets have a value on realisation in the ordinary course
of the Company’s business, which is at least to the amount at which they are stated in the balance sheet.
2013-14
5,442,721 --------
Particulars
Deferred Tax Liability (Net)
2014-15
CASH FLOW STATEMENT FOR THE YEAR ENDED 31st March 2015
2014-2015 2013-2014
In Rs. In Rs.
A. Cash Flow from Operating Activities
Net Profit before tax and extraordinary items (302,559,516) (320,291,397)
Net Cash inflow from Financing Activities (C) (204,976,508) (70,094,979)
Net Increase/(Decrease) in Cash Flow (A+B+C) (11,777,629) (6,907,015)
Opening Balance of Cash and Cash Equivalent 14,195,284 21,102,299
Closing Balance of Cash and Cash Equivalent 2,417,655 14,195,284
As per our report of even date
for Mukesh Mehta & Associates,
For and on behalf of the Board
Chartered Accountants
Mukesh Mehta Ajit Kamath Manoj Jain
Proprietor Chairman Director
FRN: 116309WMem.No. 100407
Place : Mumbai Rajendra Kaimal Jignesh Patel
Date: 29.05.2015 Director Company Secretary
-
Avon Lifesciences Ltd
5554
22nd ANNUAL REPORT
AUDITORS' CERTIFICATE FOR CASH FLOW
To
The Board of Directors,
AVON ORGANICS LIMITED
We have examined the attached cash flow statements of M/s. AVON ORGANICS LIMITED for the year ended 31st March, 2015. The statement has been prepared by the company in accordance with the requirements of Clause 32 of the Listing Agreement and is based on and in agreement with the corresponding Profit and Loss Account and Balance Sheet of the Company covered by our Report of dated May 29, 2015 to the members of the Company.
For Mukesh Mehta & Associates
Chartered Accountants.
Sd/-
Mukesh Mehta
Proprietor
Membership No. 100407
FRN:116309W
Place: Mumbai
Date: 29.05.2015
FORM NO. MGT 11Proxy Form
[Pursuant to Section 105 (6) of the Companies Act, 2013 (the Act) and Rule 19 (3) of the Companies(Management and Administration) Rules , 2014]
Email Id :________________________________________ Signature:_______________________, ndAs my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 22 ANNUAL GENERAL MEETING of
the Company, to be held on Wednesday, 30th September, 2015 at 10 a.m. at Hotel Daspalla, Road No. 37, Jubilee Hills, Hyderabad – 500033, Telangana, and at any adjournment thereof in respect of such resolutions as are indicated below:
Signed this ___________day of _____________2015
Signature of Shareholder ______________________
Signature of Proxyholder (s) ___________________
Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the meeting.
Resolution No.
Resolution
1.To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2015, together with the Reports of the Board of Directors and the Auditors thereon.
2.To appoint a Director in place of Mr. Ajit Kamath (DIN: 00032799), who retires by rotation and is eligible for re-appointment.
3.To appoint a Director in place of Mr. Rajendra Kaimal (DIN: 00032839), who retires by rotation and is eligible for re-appointment.
4. Ratify the Appointment of Statutory Auditors
5. Appointment of Ms. Zeenat Pathan (DIN: 07153363) as an Independent Director.
6. Appointment of Ms. Komal Jajodia (DIN: 05186391) as an Independent Director.
7. Re-Designate Mr. Manoj Jain as Whole-time Director.
8. Ratification for the relevant date mentioned in notice of postal ballot dated June 09, 2015.
PLEASE COMPLETE THIS ATTENDACE SLIP AND HAND IT OVER AT THE ENTRANCE OF THE HALL
Full Name of the Member (in BLOCK LETTERS) ________________________________________________________
DP ID *: _______________________________ Client ID : _____________________________________________
Regd. Folio No.: __________________________ No. of Shares held : ______________________________________
Full Name of the Proxy (in BLOCK LETTERS) __________________________________________________________
ndI hereby record my presence at the 22 Annual General Meeting of the Company on Wednesday, 30th September, 2015 at 10 a.m. at Hotel Daspalla, Road No. 37, Jubilee Hills, Hyderabad – 500033, Telangana,
Electronic Voting Sequence Number (EVSN) : 150903001
Signature of Member/ Proxy ______________________________________________________________________
*Applicable to investors holding shares in electronic form